Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14640645 | 0.81 | NAAA (0.44) | GPR119RAB9ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL14640643 | 0.81 | GPR119 (0.48) | GPR119TSHRRECQLSMN1; SMN2LMNA | |
| SCHEMBL13186625 | 0.80 | NAAA (0.42) | GPR119RAB9ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL27734720 | 0.80 | GPR119 (0.64) | GPR119RAB9ATSHRRECQLSMN1; SMN2 | |
| SCHEMBL31643339 | 0.80 | GPR119 (0.70) | GPR119RAB9ATSHRRECQLSMN1; SMN2 | |
| SCHEMBL1069801 | 0.79 | GPR119 (0.74) | GPR119RAB9ATSHRRECQLSMN1; SMN2 | |
| SCHEMBL388894 | 0.79 | GPR119 (0.60) | GPR119RAB9ATSHRRECQLSMN1; SMN2 | |
| SCHEMBL1724928 | 0.78 | NAAA (0.43) | GPR119RAB9ATSHRSMN1; SMN2NPC1 | |
| SCHEMBL27734753 | 0.78 | TSHR (0.78) | RAB9ATSHRRECQLSMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL612389 | 0.77 | NAAA (0.42) | GPR119RAB9ATSHRSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207147-B2 | Heterocyclic derivatives as GPCR receptor agonists | PROSIDION LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1711491-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | Prosidion Limited (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005061489-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281060-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | GPR119, GCGR, GLP1R | GPR119 1/4885RAB9A 834/4885TSHR 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.